Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
about
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell TransplantationAcute graft-versus-host disease: a bench-to-bedside update.Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A ReviewSinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxisA prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantationImproved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosisA phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).Graft-versus-host disease: state of the science.Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationSirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell TransplantationHigh-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisThe novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failureSafety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial.Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Use of defibrotide in the treatment and prevention of veno-occlusive disease.TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions.Evi1 forms a bridge between the epigenetic machinery and signaling pathways.
P2860
Q26740251-AE3CAAD9-17C4-4C0A-9E96-0912CD61C9DBQ27687130-EA8A60A7-8521-495C-BC10-D538B2C841BCQ28074157-86EFB6E3-CF74-4802-8864-1A1A401480E0Q28083417-342F6C60-5AFF-4492-A5C9-13D6AD7A5BBBQ33387336-A9CD3ACC-55DD-413F-B40D-0120FA63EDE8Q33403897-D8258098-161F-4772-851D-C21329918A80Q33573529-C93A7A1F-6625-4A7C-BA70-FDFA471B1724Q33643387-B771C23B-F2C3-4E11-81E8-FFF5330B4377Q33924570-8BFF2EA6-3331-4572-B47C-F21C5E9431CBQ33977923-C8A424A9-BF15-4804-B3CA-E01ECE695309Q34077792-7A729B64-487F-405E-BAB0-28FD545769AFQ34207695-DA08188C-1AD5-40E4-8CAC-D65CF02CCAA4Q34272554-823F2797-B0DD-43D3-B585-7F11A6D43230Q34451427-1E1EDD7C-FAC5-4B9B-A50F-7AA2D4885F73Q34479575-90C6E5CE-B999-4DE0-9B64-24EE421F6E18Q34510280-DB908FC6-D695-4550-94C8-4B7B3313CD13Q34983459-489EE87F-BD34-422A-9345-ED6E8C434B3AQ35029393-FD97898C-64D9-4EB3-911D-1A974993FBACQ35054593-74544C3E-7A29-4F8D-9173-032E60FE0BECQ35184589-AF2BDB0A-D86C-4AC3-B4DE-F559DD972CF8Q35231363-6142352D-271E-48A8-8D97-25BB8522BAE0Q35499395-540E8D27-55DC-4734-943A-5CAE4231718DQ36055238-B8E4A1BF-321E-41C0-A7CA-EBD947D529A3Q36117735-5E4A691E-EE06-4B28-96E0-BA8EE753062CQ36206849-374E13D0-89FA-42AB-A44D-4DD6A1234688Q36216192-C27E4CAA-6B76-465C-B395-DB8D19FD4E7CQ36662042-EBAE67DD-46FE-4AF9-BBA5-3BE7C9A72455Q36755484-6FAA0B1F-8D2E-4720-B33C-98C316AB1F11Q36768621-FB79570F-EA0B-4A39-8E48-9259F963F4C8Q36862464-8B8974E4-30C2-42EC-9810-78E1677B9DF4Q36980277-87612779-9DB4-4B5A-9CC3-518AFC1C14FAQ37073000-C51BDAEC-AC57-4528-979D-15C2747CBD36Q37184046-87557062-FEE9-44A7-9033-3AD6555AEA61Q37247581-0EA568C8-A8CF-4F33-8256-6B8375666674Q37618931-C682D4A1-C284-47F0-9293-8EA1CFE2FE11Q37621636-E04D2654-4CC7-44E0-87A9-69DD840BF359Q37670062-A104F86C-3243-4148-99FB-2A7F4E1B188CQ37810075-A5ECEBED-7E1A-45DB-95DD-3ACF9490E55FQ37813013-58938AFD-5EAC-4CAA-BA7B-268BD8278FF8Q37906986-6AC482F7-43A3-46AD-A583-1FBA4DCD4545
P2860
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sirolimus is associated with v ...... eic stem cell transplantation.
@en
Sirolimus is associated with v ...... eic stem cell transplantation.
@nl
type
label
Sirolimus is associated with v ...... eic stem cell transplantation.
@en
Sirolimus is associated with v ...... eic stem cell transplantation.
@nl
prefLabel
Sirolimus is associated with v ...... eic stem cell transplantation.
@en
Sirolimus is associated with v ...... eic stem cell transplantation.
@nl
P2093
P2860
P1433
P1476
Sirolimus is associated with v ...... eic stem cell transplantation.
@en
P2093
Carolyn Revta
Corey Cutler
Diane Warren
Edwin Alyea
Erica Linden
Haesook T Kim
John Koreth
Joseph H Antin
Kristen Stevenson
Mary Horowitz
P2860
P304
P356
10.1182/BLOOD-2008-07-169342
P407
P577
2008-09-05T00:00:00Z